Cooley's leadership in corporate representation and mergers and acquisition counseling for life science companies provides a deep foundation of experience upon which we have established a dedicated team of corporate partnering and licensing attorneys.
Our senior team members are internationally recognized as being the best in their field. Many of our professionals are backed by a wealth of supporting experience, having been pharmaceutical marketing specialists, business consultants, financial leaders, biotech researchers and in-house counsel at life science companies.
We have a solid understanding of the drug development and regulatory environment, expertise in early-stage R&D, late stage product deals, particular expertise in late-stage compound deals and specific knowledge of the sensitivities surrounding commercialization issues such as:
- Indication splitting
- Off-label sales
- Product bundling
Key Facts
- 25 dedicated professionals exclusively focused on corporate partnering, licensing and other commercial transactions specific to the life science industry
- Nearly one third of the attorneys in the group have advanced degrees in relevant scientific disciplines
- Many of the attorneys speak multiple languages and work extensively on cross-border transactions
Rankings and Accolades
Cooley clients are in bold.
- Named "Law Firm of the Year" in Biotechnology by US News – Best Lawyers
- Ranked #1 among U.S. law firms for number of attorneys included in Biotech Law category of Best Lawyers in America
- Ranked #1 in Life Sciences by Chambers USA: America's Leading Lawyers for Business in 2007, 2008, 2009, 2010 and 2011
- Consistently ranked #1 in the BioPharm Insight Biotechnology and Pharmaceutical Licensing League Table Report for 2010 and 2011 YTD
- Ranked #1 in issuer-side Life Science IPOs from 2000 to present (Source: IPO Vital Signs)
- Ranked in top 10 nationally as underwriters' counsel for life sciences IPOs filed from 2004 to 2010 (Source: IPO Vital Signs)
- Ranked #1 in 2010 and #2 in 2008 and 2009 in the U.S. for representation of venture-backed Biotech/Pharmaceuticals companies (Source: VentureSource)
- Ranked #1 among U.S. law firms for number of attorneys included in Biotech Law category of Best Lawyers in America
- Allicense "Breakthrough Deal of the Year" awarded to Cooley transactions:
- 2010: Seattle Genetics/Millennium (nominated) & Amylin Pharmaceuticals/Takeda (nominated)
- 2009: Exelixis, Inc./Bristol-Meyers Squibb (also nominated: Medivation, Inc./Pfizer, Inc.)
- 2007: Affymax/ Takeda
- 2006: Nuvelo/ Bayer
- 2003: Eli Lilly/Amylin (also nominated: GSK/Exelixis)
- 2002: Eli Lilly/ISIS Pharmaceuticals (also nominated: BMS/Exelixis)
- 2000: Innovex/CV Therapeutics
Related Practices
Related Industries
|